Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Q2 2026 · 10-Q
Revenue$2.74B$2.74B+3.4% vs Q2 2025 Net Income$97.50M$97.50M−84.6% vs Q2 2025 EPS Diluted$0.66$0.66−84.8% vs Q2 2025 Operating Cash Flowderived$448,900,000+179.0% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
Free Cash Flowderived$408,000,000+203.8% Margins · derivedNet margin3.6%−20.4 pt vs Q2 2025
ended Jun 30, 2026 · filed Jul 29, 2026 · 29 d after period end